|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Več možnosti |
|
|
© 2024 SFX by Ex Libris Inc. | Piškotki
CrossRef Omogočeno
|